Serine Hydroxymethyltransferase 2 (SHMT2) is a mitochondrial enzyme that catalyzes the reversible conversion of L-serine and tetrahydrofolate (THF) to glycine and 5,10-methylene-THF, generating one-carbon units essential for nucleotide synthesis, Methylation reactions, and mitochondrial redox balance. It is upregulated in rapidly proliferating cells including activated T cells, Cancer cells, and healing tissues, making it a metabolic bottleneck for cell division and immune responses.
Imagine SHMT2 as a specialized recycling plant inside a mitochondrial factory. Raw material (serine) arrives at the loading dock, and SHMT2 workers dismantle it into two valuable products: glycine (the protein-building material sent to the Collagen biosynthesis pathway department) and a one-carbon unit (packaged as 5,10-methylene-THF β think of it as a "carbon voucher" that can be cashed in for DNA building blocks or Methylation currency). The plant runs in reverse too: when glycine is abundant but serine is scarce, SHMT2 workers reassemble glycine back into serine. This plant runs overtime during growth spurts, wound repair, and immune battles β anytime the factory needs to build new cells fast. Cancer cells hijack this plant to run at maximum capacity 24/7, churning out carbon vouchers to fuel their relentless division. Shut down SHMT2, and the entire assembly line for new DNA stalls β no nucleotides, no cell division.
SHMT2 operates at the entry point of mitochondrial one-carbon metabolism, a metabolic hub that supports multiple anabolic processes:
Forward reaction (serine breakdown):
L-serine + tetrahydrofolate (THF) β glycine + 5,10-methylene-THF + HβO
Reverse reaction (serine synthesis):
glycine + 5,10-methylene-THF + HβO β L-serine + THF
The enzyme requires Vitamin B6 (pyridoxal-5'-phosphate, PLP) as an obligate cofactor bound to the active site. The reaction proceeds through a quinonoid intermediate stabilized by the PLP cofactor, allowing the Ξ±-carbon of serine to be transferred to THF.
Downstream one-carbon unit distribution:
graph TD
A["L-serine + THF"] -->|"SHMT2 + PLP"| B["Glycine + 5,10-methylene-THF"]
B --> C[Purine synthesis via ATIC/GART]
B --> D[Thymidine synthesis via TYMS]
B --> E[MTHFD2 oxidation]
E --> F[10-formyl-THF for purine synthesis]
E --> G[Formate export to cytosol]
B --> H[MTHFD2L reduction]
H --> I[5,10-methenyl-THF]
I --> J[5-MTHF via MTHFR]
J --> K[Methionine cycle/Methylation]
B --> L["MTHFD2 via NADP+"]
L --> M[NADPH production for redox]
A --> N[Glycine for collagen]
Transcriptional regulation:
- HIF-1Ξ± upregulates SHMT2 under hypoxia via direct binding to hypoxia response elements (HREs) in the SHMT2 promoter
- c-Myc drives SHMT2 expression in proliferating cells and Cancer
- mTORC1 signaling increases SHMT2 via ATF4 during amino acid stress
- FOXO transcription factors suppress SHMT2 during nutrient restriction
Integration with metabolic reprogramming:
SHMT2 expression increases 5-20 fold in activated T cells within 24-48 hours of TCR stimulation, supporting clonal expansion. In Cancer cells, SHMT2 flux can account for >50% of one-carbon units entering nucleotide synthesis, making it a rate-limiting enzyme for tumor growth. The mitochondrial folate cycle involving SHMT2 β MTHFD2 β MTHFD1L generates NADPH (via ALDH1L2), contributing to mitochondrial redox defense alongside the pentose phosphate pathway.
Serine-glycine interconversion:
The reversibility of SHMT2 allows metabolic flexibility: when serine is abundant (e.g., postprandial state or high-protein diet), the forward reaction dominates, producing one-carbon units and glycine. When glycine accumulates (e.g., Collagen biosynthesis pathway breakdown), the reverse reaction can synthesize serine de novo from glycine, conserving amino acids.
SHMT2 is a master regulator of proliferative capacity across multiple clinical contexts:
Cancer metabolism:
SHMT2 is one of the most consistently upregulated metabolic enzymes across cancer types, including non-small cell lung cancer, glioblastoma, breast cancer, and leukemia. Tumor SHMT2 expression correlates with poor prognosis and chemoresistance. SHMT2 inhibition (pharmacological or genetic) selectively kills cancer cells while sparing normal cells β a therapeutic window exploited by experimental SHMT inhibitors currently in preclinical development. This aligns with the Selfish Brain and selfish immune system concepts: cancer cells commandeer SHMT2 to monopolize one-carbon units at the expense of host immunity and repair.
Immune function:
T cell activation requires a 10-100 fold increase in biomass within 48-72 hours to support clonal expansion. SHMT2 is essential for this response: SHMT2 knockout T cells fail to proliferate after antigen stimulation, even in nutrient-replete conditions. Macrophage Polarization also depends on SHMT2: M1 macrophages upregulate SHMT2 to support inflammatory cytokine production and ROS generation, while M2 macrophages downregulate it, favoring oxidative metabolism. Chronic low-grade inflammation (metaflammation) maintains constitutive SHMT2 expression in circulating leukocytes, creating a "primed" state that consumes serine and depletes one-carbon reserves.
Wound healing:
SHMT2 expression spikes 3-5 fold in healing wounds, driven by HIF-1Ξ± in the hypoxic wound bed. This supports fibroblast proliferation, Collagen biosynthesis pathway (via glycine production), and keratinocyte migration. Impaired wound healing in diabetes and chronic stress may involve SHMT2 dysregulation: hyperglycemia and cortisol suppress SHMT2 via FOXO activation, starving healing tissues of nucleotides.
Evolutionary mismatch:
The hunter-gatherer diet provided abundant glycine from bone broths, connective tissue, and organ meats, reducing SHMT2 demand for serine-to-glycine conversion. Modern diets are muscle-meat dominant, providing excess serine but insufficient glycine (ratio ~3:1 instead of ancestral ~1:1). This forces SHMT2 to run continuously in the forward direction, depleting tetrahydrofolate pools and creating a folate "functional deficiency" even when folate intake is adequate. Supplementing glycine (10-15 g/day) or consuming collagen-rich foods can reverse this imbalance.
Intervention implications:
- Support SHMT2 function: Ensure adequate serine (eggs, soy, nuts), folate (leafy greens, liver), Vitamin B6 (fish, poultry), and glycine (collagen, bone broth) to maintain one-carbon metabolism during immune activation or wound healing
- Glycine supplementation: 10-15 g/day glycine can spare serine, reduce SHMT2 flux, and preserve Methylation capacity
- Cancer context: Dietary serine/glycine restriction (experimental) may limit SHMT2-dependent tumor growth, but must be balanced against immune and repair needs
- Hypoxia training: Controlled hypoxic exposure (e.g., intermittent hypoxic training) upregulates SHMT2 and mitochondrial one-carbon capacity, potentially enhancing metabolic resilience
- SHMT2 is localized exclusively to mitochondria, while SHMT1 is cytoplasmic β they are encoded by separate genes with distinct regulation
- SHMT2 knockout is embryonically lethal in mice by day E9.5, indicating indispensability for early development
- Requires pyridoxal-5'-phosphate (Vitamin B6) as cofactor; B6 deficiency reduces SHMT2 activity by 50-70%
- Expression increases 5-20 fold in activated T cells, 10-50 fold in many cancers, and 3-5 fold in healing wounds
- Provides >50% of one-carbon units for nucleotide synthesis in proliferating cells
- Catalyzes a reversible reaction with equilibrium constant Keq β 1.2, allowing bidirectional flux
- Upregulated by HIF-1Ξ±, c-Myc, mTORC1/ATF4; suppressed by FOXO transcription factors
- SHMT2 flux generates NADPH via the mitochondrial folate cycle, contributing 10-20% of mitochondrial antioxidant capacity
- Glycine produced by SHMT2 accounts for 30-40% of total glycine used in Collagen biosynthosis pathway
- SHMT2 inhibitors (e.g., SHIN1, SHIN2) selectively kill cancer cells in vitro and in vivo without affecting normal cell proliferation
- Single nucleotide polymorphisms (SNPs) in SHMT2 are rare but associated with neural tube defects when combined with folate deficiency
- 5-MTHF β SHMT2-derived 5,10-methylene-THF is reduced to 5-MTHF by MTHFR, supplying methyl groups for the Methylation Cycle
- Methylation Cycle β SHMT2 provides one-carbon units that ultimately feed into homocysteine remethylation and SAM production
- glycine β direct product of SHMT2 activity; essential substrate for Collagen biosynthesis pathway, glutathione synthesis, and purine synthesis
- serine β primary substrate for SHMT2; depleted rapidly during immune activation and cancer growth
- folate β SHMT2 requires tetrahydrofolate as one-carbon acceptor; folate deficiency impairs SHMT2 flux
- Vitamin B6 β obligate cofactor for SHMT2 enzyme activity; deficiency reduces SHMT2 function by 50-70%
- mitochondria β SHMT2 is the mitochondrial gatekeeper of one-carbon metabolism, distinct from cytoplasmic SHMT1
- T cells β SHMT2 is upregulated 10-20 fold during T cell activation; essential for clonal expansion
- Cancer β one of the most consistently upregulated enzymes in cancer; drives nucleotide synthesis for rapid proliferation
- DNA repair β SHMT2 provides dTMP and purines required for DNA synthesis during repair
- wound healing β upregulated 3-5 fold in healing tissues to support fibroblast proliferation and Collagen biosynthesis pathway
- NADPH β SHMT2 indirectly generates NADPH via the mitochondrial folate cycle (MTHFD2 β ALDH1L2), supporting antioxidant defense
- immune activation β all proliferating immune cells upregulate SHMT2 to meet nucleotide demands
- Macrophage Polarization β M1 macrophages upregulate SHMT2 for inflammatory metabolism; M2 macrophages downregulate it
- HIF-1 β transcriptionally upregulates SHMT2 under hypoxia to support Anaerobic Glycolysis and nucleotide synthesis
- Collagen biosynthesis pathway β glycine produced by SHMT2 provides 30-40% of glycine residues in collagen triple helices
- MTHFR β works downstream of SHMT2 to convert 5,10-methylene-THF to 5-MTHF for Methylation
- purine synthesis β SHMT2 provides 10-formyl-THF (via MTHFD2) for purine ring formation at two steps (C2 and C8 positions)
- oxidative stress β SHMT2-derived NADPH supports glutathione reductase and thioredoxin reductase for redox homeostasis
- inflammation β chronic inflammation maintains constitutive SHMT2 expression in circulating leukocytes, depleting serine and folate
- mTORC1 β activates SHMT2 transcription via ATF4 during amino acid stress or growth factor signaling
- FOXO β suppresses SHMT2 expression during nutrient restriction, reducing anabolic metabolism
- Chronic Low-Grade Inflammation β metaflammation drives chronic SHMT2 upregulation in leukocytes, creating functional folate deficiency
- homocysteine β when SHMT2 depletes tetrahydrofolate pools, homocysteine accumulates due to impaired remethylation